Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 21 | 2024 | 351 | 4.760 |
Why?
|
Product Surveillance, Postmarketing | 20 | 2024 | 463 | 3.930 |
Why?
|
Confidentiality | 10 | 2023 | 607 | 2.860 |
Why?
|
Angioedema | 8 | 2023 | 184 | 2.860 |
Why?
|
Multicenter Studies as Topic | 9 | 2023 | 1731 | 2.680 |
Why?
|
United States Food and Drug Administration | 32 | 2024 | 1672 | 2.510 |
Why?
|
Research Design | 20 | 2024 | 6207 | 1.970 |
Why?
|
Databases, Factual | 42 | 2024 | 8062 | 1.960 |
Why?
|
Privacy | 6 | 2023 | 232 | 1.850 |
Why?
|
Information Dissemination | 6 | 2025 | 1140 | 1.770 |
Why?
|
Comparative Effectiveness Research | 9 | 2018 | 713 | 1.750 |
Why?
|
International Classification of Diseases | 15 | 2022 | 933 | 1.610 |
Why?
|
Propensity Score | 18 | 2024 | 1967 | 1.560 |
Why?
|
Computer Security | 5 | 2023 | 261 | 1.540 |
Why?
|
Adverse Drug Reaction Reporting Systems | 11 | 2024 | 497 | 1.460 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 8 | 2023 | 1514 | 1.410 |
Why?
|
Fluoroquinolones | 2 | 2023 | 307 | 1.370 |
Why?
|
Epidemiologic Research Design | 5 | 2019 | 368 | 1.360 |
Why?
|
Clinical Coding | 5 | 2021 | 188 | 1.360 |
Why?
|
Drug Prescriptions | 11 | 2020 | 1662 | 1.300 |
Why?
|
Sentinel Surveillance | 7 | 2024 | 292 | 1.160 |
Why?
|
Electronic Health Records | 24 | 2024 | 4864 | 1.110 |
Why?
|
Adamantane | 3 | 2017 | 148 | 1.110 |
Why?
|
Information Storage and Retrieval | 3 | 2022 | 832 | 1.100 |
Why?
|
Models, Statistical | 10 | 2024 | 5089 | 1.070 |
Why?
|
Gastrointestinal Hemorrhage | 6 | 2023 | 1127 | 1.050 |
Why?
|
Dipeptides | 3 | 2017 | 386 | 1.030 |
Why?
|
Algorithms | 20 | 2024 | 14062 | 1.020 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2024 | 317 | 1.000 |
Why?
|
Gastric Bypass | 8 | 2023 | 820 | 1.000 |
Why?
|
Drug Therapy | 2 | 2019 | 504 | 0.930 |
Why?
|
Data Collection | 7 | 2020 | 3317 | 0.910 |
Why?
|
Drug Utilization | 5 | 2018 | 1187 | 0.910 |
Why?
|
Bariatric Surgery | 8 | 2022 | 997 | 0.890 |
Why?
|
Antidepressive Agents | 7 | 2024 | 2902 | 0.860 |
Why?
|
Anti-Bacterial Agents | 13 | 2023 | 7476 | 0.860 |
Why?
|
Medication Errors | 2 | 2019 | 786 | 0.840 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1238 | 0.820 |
Why?
|
Hypoglycemic Agents | 11 | 2023 | 3107 | 0.800 |
Why?
|
Insurance | 1 | 2023 | 115 | 0.790 |
Why?
|
Choledocholithiasis | 1 | 2022 | 50 | 0.770 |
Why?
|
United States | 70 | 2025 | 72896 | 0.750 |
Why?
|
Pregnancy Complications | 8 | 2018 | 2970 | 0.750 |
Why?
|
Cholecystitis, Acute | 1 | 2022 | 81 | 0.750 |
Why?
|
Warfarin | 7 | 2023 | 1494 | 0.740 |
Why?
|
Cholangitis | 1 | 2022 | 110 | 0.740 |
Why?
|
Drug Labeling | 3 | 2019 | 251 | 0.730 |
Why?
|
Trazodone | 1 | 2020 | 67 | 0.720 |
Why?
|
Proportional Hazards Models | 18 | 2025 | 12520 | 0.710 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 95 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 13 | 2024 | 12235 | 0.710 |
Why?
|
Pharmaceutical Preparations | 6 | 2023 | 1084 | 0.700 |
Why?
|
Antihypertensive Agents | 3 | 2021 | 2033 | 0.690 |
Why?
|
Humans | 179 | 2025 | 765823 | 0.690 |
Why?
|
Pregnancy Outcome | 8 | 2024 | 2968 | 0.680 |
Why?
|
Poisson Distribution | 4 | 2019 | 508 | 0.680 |
Why?
|
Obesity, Morbid | 6 | 2022 | 1293 | 0.660 |
Why?
|
Incretins | 1 | 2019 | 100 | 0.620 |
Why?
|
Hypoglycemia | 2 | 2023 | 896 | 0.610 |
Why?
|
Cohort Studies | 36 | 2024 | 41643 | 0.610 |
Why?
|
Mefenamic Acid | 1 | 2018 | 5 | 0.610 |
Why?
|
Equipment and Supplies | 3 | 2020 | 273 | 0.600 |
Why?
|
Prescriptions | 5 | 2022 | 388 | 0.590 |
Why?
|
Computer Communication Networks | 4 | 2023 | 292 | 0.590 |
Why?
|
Information Services | 1 | 2019 | 240 | 0.580 |
Why?
|
Diclofenac | 1 | 2018 | 68 | 0.580 |
Why?
|
Naproxen | 1 | 2018 | 99 | 0.570 |
Why?
|
Drug Monitoring | 2 | 2014 | 960 | 0.570 |
Why?
|
Self-Injurious Behavior | 1 | 2023 | 572 | 0.560 |
Why?
|
Morning Sickness | 1 | 2017 | 6 | 0.560 |
Why?
|
National Health Programs | 1 | 2020 | 443 | 0.560 |
Why?
|
Statistics as Topic | 2 | 2014 | 2350 | 0.550 |
Why?
|
Central Nervous System Stimulants | 3 | 2018 | 1167 | 0.540 |
Why?
|
Niacin | 1 | 2017 | 116 | 0.540 |
Why?
|
Insurance Claim Review | 3 | 2020 | 744 | 0.530 |
Why?
|
Influenza, Human | 4 | 2022 | 1539 | 0.530 |
Why?
|
Photosensitizing Agents | 1 | 2021 | 626 | 0.530 |
Why?
|
Ibuprofen | 1 | 2018 | 228 | 0.530 |
Why?
|
Taiwan | 3 | 2023 | 522 | 0.520 |
Why?
|
Ondansetron | 1 | 2017 | 95 | 0.520 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.520 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2687 | 0.510 |
Why?
|
Risk Adjustment | 1 | 2019 | 596 | 0.510 |
Why?
|
Aortic Aneurysm | 1 | 2020 | 649 | 0.510 |
Why?
|
Prenatal Care | 3 | 2018 | 1157 | 0.500 |
Why?
|
Gastrectomy | 7 | 2023 | 692 | 0.490 |
Why?
|
Carcinoma, Basal Cell | 1 | 2021 | 565 | 0.490 |
Why?
|
Antiemetics | 1 | 2017 | 185 | 0.480 |
Why?
|
Health Care Surveys | 4 | 2016 | 2424 | 0.480 |
Why?
|
Pregnancy | 33 | 2024 | 30215 | 0.480 |
Why?
|
Drug Approval | 7 | 2021 | 818 | 0.470 |
Why?
|
Myocardial Infarction | 8 | 2022 | 11506 | 0.470 |
Why?
|
Female | 93 | 2024 | 396050 | 0.460 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2269 | 0.460 |
Why?
|
Pregnancy Trimester, First | 4 | 2022 | 917 | 0.460 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2018 | 318 | 0.450 |
Why?
|
Cardiovascular System | 2 | 2019 | 840 | 0.440 |
Why?
|
Population Surveillance | 5 | 2018 | 2595 | 0.440 |
Why?
|
Computer Simulation | 11 | 2024 | 6252 | 0.440 |
Why?
|
Software | 4 | 2017 | 4458 | 0.440 |
Why?
|
Pregnancy Trimesters | 4 | 2018 | 197 | 0.440 |
Why?
|
Aortic Valve | 1 | 2023 | 1966 | 0.430 |
Why?
|
Antiviral Agents | 6 | 2022 | 3051 | 0.430 |
Why?
|
Meta-Analysis as Topic | 2 | 2015 | 1366 | 0.430 |
Why?
|
Estrogen Replacement Therapy | 2 | 2010 | 1206 | 0.430 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 608 | 0.420 |
Why?
|
Bupropion | 2 | 2024 | 303 | 0.420 |
Why?
|
Intracranial Hemorrhages | 2 | 2018 | 810 | 0.410 |
Why?
|
Pancreatitis | 1 | 2019 | 1087 | 0.410 |
Why?
|
Adult | 61 | 2024 | 223055 | 0.410 |
Why?
|
Hyperlipidemias | 1 | 2017 | 770 | 0.410 |
Why?
|
Research Personnel | 1 | 2017 | 590 | 0.400 |
Why?
|
Medroxyprogesterone Acetate | 2 | 2010 | 153 | 0.400 |
Why?
|
Selection Bias | 4 | 2022 | 359 | 0.390 |
Why?
|
Middle Aged | 58 | 2024 | 223016 | 0.390 |
Why?
|
Probability | 6 | 2023 | 2475 | 0.390 |
Why?
|
Anti-Asthmatic Agents | 4 | 2020 | 572 | 0.390 |
Why?
|
Glyburide | 3 | 2023 | 117 | 0.390 |
Why?
|
Antirheumatic Agents | 3 | 2019 | 1362 | 0.390 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2013 | 1061 | 0.380 |
Why?
|
Regression Analysis | 4 | 2019 | 6320 | 0.380 |
Why?
|
Incidence | 13 | 2024 | 21501 | 0.380 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2018 | 3718 | 0.380 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 287 | 0.380 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 180 | 0.380 |
Why?
|
Young Adult | 36 | 2022 | 59849 | 0.370 |
Why?
|
Oseltamivir | 3 | 2022 | 75 | 0.370 |
Why?
|
Quinoxalines | 1 | 2013 | 296 | 0.370 |
Why?
|
Nicotinic Agonists | 1 | 2013 | 266 | 0.370 |
Why?
|
Benzazepines | 1 | 2013 | 308 | 0.360 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2307 | 0.360 |
Why?
|
Clindamycin | 2 | 2023 | 138 | 0.360 |
Why?
|
Odds Ratio | 4 | 2025 | 9653 | 0.360 |
Why?
|
Anticoagulants | 5 | 2020 | 4862 | 0.350 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2024 | 4350 | 0.350 |
Why?
|
Outpatients | 1 | 2018 | 1591 | 0.350 |
Why?
|
Stroke | 7 | 2023 | 9749 | 0.340 |
Why?
|
Dementia | 3 | 2023 | 2743 | 0.330 |
Why?
|
Pregnancy, Unplanned | 1 | 2010 | 85 | 0.330 |
Why?
|
Perinatal Care | 2 | 2013 | 243 | 0.330 |
Why?
|
Heart Failure | 3 | 2019 | 11838 | 0.330 |
Why?
|
Adolescent | 33 | 2022 | 88794 | 0.320 |
Why?
|
Brain Ischemia | 1 | 2022 | 3001 | 0.310 |
Why?
|
Retrospective Studies | 36 | 2024 | 81505 | 0.310 |
Why?
|
Live Birth | 4 | 2022 | 516 | 0.310 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 274 | 0.300 |
Why?
|
Aged | 34 | 2024 | 171178 | 0.300 |
Why?
|
Male | 55 | 2024 | 363740 | 0.300 |
Why?
|
Atrial Fibrillation | 5 | 2022 | 5187 | 0.300 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3251 | 0.300 |
Why?
|
Contraceptives, Oral | 1 | 2010 | 559 | 0.290 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 737 | 0.290 |
Why?
|
Drug Utilization Review | 3 | 2018 | 248 | 0.290 |
Why?
|
Gestational Age | 3 | 2022 | 3614 | 0.280 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 2771 | 0.280 |
Why?
|
Biostatistics | 1 | 2008 | 162 | 0.270 |
Why?
|
Delivery of Health Care | 6 | 2024 | 5368 | 0.270 |
Why?
|
Hospitalization | 9 | 2024 | 10803 | 0.260 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2532 | 0.260 |
Why?
|
Ambulatory Care | 2 | 2016 | 2776 | 0.260 |
Why?
|
Risk Factors | 19 | 2024 | 74853 | 0.260 |
Why?
|
Prevalence | 11 | 2021 | 15832 | 0.260 |
Why?
|
Cardiomyopathies | 1 | 2018 | 2066 | 0.260 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 2 | 2017 | 109 | 0.260 |
Why?
|
Birth Certificates | 4 | 2013 | 71 | 0.260 |
Why?
|
Antipsychotic Agents | 3 | 2019 | 3076 | 0.260 |
Why?
|
Anticonvulsants | 3 | 2022 | 1919 | 0.250 |
Why?
|
Delivery, Obstetric | 1 | 2013 | 945 | 0.250 |
Why?
|
Fetal Growth Retardation | 1 | 2009 | 591 | 0.250 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4046 | 0.240 |
Why?
|
Body Height | 2 | 2022 | 1561 | 0.240 |
Why?
|
Sulfonylurea Compounds | 2 | 2017 | 220 | 0.240 |
Why?
|
Suicide | 2 | 2018 | 1606 | 0.240 |
Why?
|
Insulin, Long-Acting | 2 | 2017 | 59 | 0.240 |
Why?
|
Depressive Disorder | 2 | 2019 | 3711 | 0.230 |
Why?
|
Infant, Newborn | 14 | 2021 | 26337 | 0.230 |
Why?
|
Logistic Models | 6 | 2020 | 13266 | 0.220 |
Why?
|
Sulbactam | 1 | 2023 | 32 | 0.220 |
Why?
|
Follow-Up Studies | 11 | 2020 | 39226 | 0.220 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2023 | 32 | 0.220 |
Why?
|
Thiazolidinediones | 2 | 2017 | 459 | 0.220 |
Why?
|
Medicare | 3 | 2024 | 6816 | 0.220 |
Why?
|
Ampicillin | 1 | 2023 | 138 | 0.220 |
Why?
|
Body Mass Index | 8 | 2021 | 13041 | 0.220 |
Why?
|
Fertilization | 2 | 2019 | 197 | 0.210 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3925 | 0.210 |
Why?
|
Medical Record Linkage | 4 | 2023 | 286 | 0.210 |
Why?
|
Mood Disorders | 1 | 2009 | 1126 | 0.210 |
Why?
|
Consumer Product Safety | 2 | 2014 | 122 | 0.210 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2009 | 531 | 0.210 |
Why?
|
Cephalosporins | 1 | 2023 | 200 | 0.200 |
Why?
|
Fumarates | 2 | 2013 | 132 | 0.200 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15645 | 0.200 |
Why?
|
Neoplasms | 4 | 2021 | 22349 | 0.200 |
Why?
|
Causality | 3 | 2024 | 1247 | 0.200 |
Why?
|
Dementia, Vascular | 1 | 2023 | 126 | 0.190 |
Why?
|
Aged, 80 and over | 12 | 2020 | 59506 | 0.190 |
Why?
|
Time Factors | 13 | 2020 | 40109 | 0.190 |
Why?
|
Medication Adherence | 2 | 2010 | 2190 | 0.190 |
Why?
|
Drug Interactions | 2 | 2020 | 1416 | 0.190 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5837 | 0.190 |
Why?
|
Smoking Cessation | 1 | 2013 | 2084 | 0.180 |
Why?
|
Insurance, Medigap | 1 | 2020 | 20 | 0.180 |
Why?
|
Postmenopause | 1 | 2010 | 2517 | 0.180 |
Why?
|
Endpoint Determination | 2 | 2014 | 591 | 0.180 |
Why?
|
Amides | 2 | 2013 | 451 | 0.180 |
Why?
|
Peptic Ulcer | 1 | 2022 | 214 | 0.180 |
Why?
|
Feasibility Studies | 3 | 2022 | 5302 | 0.170 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 986 | 0.170 |
Why?
|
Mothers | 2 | 2022 | 2207 | 0.170 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4526 | 0.170 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 30 | 0.170 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12056 | 0.170 |
Why?
|
Medical Records | 5 | 2020 | 1409 | 0.170 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 30 | 0.170 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 2222 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9241 | 0.170 |
Why?
|
Case-Control Studies | 4 | 2020 | 22227 | 0.170 |
Why?
|
Child, Preschool | 13 | 2022 | 42478 | 0.170 |
Why?
|
Orphan Drug Production | 1 | 2020 | 48 | 0.160 |
Why?
|
Brain Infarction | 2 | 2018 | 285 | 0.160 |
Why?
|
Body Weight | 2 | 2021 | 4624 | 0.160 |
Why?
|
Pain, Intractable | 1 | 2020 | 132 | 0.160 |
Why?
|
Government Regulation | 2 | 2014 | 525 | 0.160 |
Why?
|
Zanamivir | 1 | 2018 | 21 | 0.160 |
Why?
|
Reference Standards | 1 | 2022 | 1013 | 0.160 |
Why?
|
Risk Assessment | 10 | 2020 | 24278 | 0.150 |
Why?
|
Stillbirth | 1 | 2022 | 381 | 0.150 |
Why?
|
Acute Disease | 3 | 2018 | 7237 | 0.150 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3834 | 0.150 |
Why?
|
Neural Tube Defects | 1 | 2020 | 256 | 0.150 |
Why?
|
Canada | 2 | 2023 | 2119 | 0.150 |
Why?
|
Pregnancy in Diabetics | 1 | 2019 | 198 | 0.150 |
Why?
|
Age Factors | 4 | 2021 | 18380 | 0.150 |
Why?
|
Asthma | 4 | 2020 | 6268 | 0.150 |
Why?
|
Health Benefit Plans, Employee | 1 | 2020 | 332 | 0.150 |
Why?
|
Diabetes, Gestational | 3 | 2019 | 1263 | 0.150 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 116 | 0.150 |
Why?
|
Glipizide | 1 | 2017 | 48 | 0.140 |
Why?
|
Schizophrenia | 3 | 2019 | 6970 | 0.140 |
Why?
|
Registries | 3 | 2018 | 8320 | 0.140 |
Why?
|
Off-Label Use | 1 | 2019 | 185 | 0.140 |
Why?
|
Premature Birth | 1 | 2009 | 1829 | 0.140 |
Why?
|
Fenofibrate | 1 | 2017 | 86 | 0.140 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 157 | 0.140 |
Why?
|
Gastroplasty | 2 | 2018 | 153 | 0.140 |
Why?
|
Infant | 10 | 2022 | 36375 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1591 | 0.140 |
Why?
|
Weight Gain | 2 | 2024 | 2355 | 0.130 |
Why?
|
Child | 17 | 2022 | 80509 | 0.130 |
Why?
|
Metformin | 2 | 2022 | 904 | 0.130 |
Why?
|
Electronics | 3 | 2022 | 314 | 0.130 |
Why?
|
Reproducibility of Results | 7 | 2024 | 20131 | 0.130 |
Why?
|
Trimethoprim | 1 | 2015 | 79 | 0.130 |
Why?
|
Legislation, Drug | 1 | 2018 | 216 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 216 | 0.130 |
Why?
|
Ultraviolet Rays | 1 | 2021 | 1099 | 0.130 |
Why?
|
Suicidal Ideation | 2 | 2023 | 1465 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5923 | 0.120 |
Why?
|
Piperidines | 1 | 2024 | 1662 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1881 | 0.120 |
Why?
|
Pilot Projects | 6 | 2021 | 8725 | 0.120 |
Why?
|
Fractures, Bone | 1 | 2007 | 2041 | 0.120 |
Why?
|
Treatment Outcome | 11 | 2024 | 65223 | 0.120 |
Why?
|
Antithrombins | 1 | 2017 | 295 | 0.120 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 518 | 0.120 |
Why?
|
Quinolines | 1 | 2020 | 770 | 0.120 |
Why?
|
Pregnancy, Multiple | 2 | 2013 | 216 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2019 | 2184 | 0.110 |
Why?
|
Rare Diseases | 1 | 2020 | 629 | 0.110 |
Why?
|
Weight Loss | 3 | 2022 | 2710 | 0.110 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 967 | 0.110 |
Why?
|
Research Subjects | 1 | 2015 | 248 | 0.110 |
Why?
|
Patient Compliance | 2 | 2018 | 2693 | 0.110 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2013 | 36 | 0.110 |
Why?
|
Drug Costs | 1 | 2021 | 1193 | 0.110 |
Why?
|
Linear Models | 2 | 2022 | 5873 | 0.110 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 1325 | 0.110 |
Why?
|
Patient Readmission | 2 | 2017 | 3284 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 533 | 0.110 |
Why?
|
Labor, Induced | 1 | 2014 | 153 | 0.110 |
Why?
|
Opioid-Related Disorders | 2 | 2021 | 2176 | 0.110 |
Why?
|
Hemorrhage | 3 | 2020 | 3464 | 0.100 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 499 | 0.100 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2015 | 336 | 0.100 |
Why?
|
Insulin | 4 | 2023 | 6601 | 0.100 |
Why?
|
Disease | 1 | 2017 | 674 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14745 | 0.100 |
Why?
|
Depressive Disorder, Major | 3 | 2019 | 4805 | 0.100 |
Why?
|
Sex Factors | 3 | 2021 | 10607 | 0.100 |
Why?
|
Health Policy | 3 | 2021 | 2699 | 0.100 |
Why?
|
Colitis, Ulcerative | 1 | 2024 | 1914 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3047 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1667 | 0.090 |
Why?
|
Predictive Value of Tests | 8 | 2020 | 15398 | 0.090 |
Why?
|
Alzheimer Disease | 2 | 2023 | 8725 | 0.090 |
Why?
|
Anaphylaxis | 1 | 2018 | 738 | 0.090 |
Why?
|
Demography | 2 | 2023 | 1640 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 1811 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2018 | 563 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1204 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 10383 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2019 | 1567 | 0.090 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5889 | 0.090 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1238 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4332 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2156 | 0.090 |
Why?
|
Goals | 1 | 2015 | 717 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2283 | 0.080 |
Why?
|
Medical Records Systems, Computerized | 2 | 2013 | 1195 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2024 | 2428 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 391 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 591 | 0.080 |
Why?
|
Pre-Eclampsia | 2 | 2009 | 1256 | 0.080 |
Why?
|
Overweight | 1 | 2020 | 2443 | 0.080 |
Why?
|
Suicide, Attempted | 1 | 2018 | 1412 | 0.080 |
Why?
|
Comorbidity | 3 | 2018 | 10570 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2013 | 696 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10723 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2016 | 634 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3444 | 0.080 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 2169 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2018 | 21064 | 0.070 |
Why?
|
Hypertension | 2 | 2018 | 8625 | 0.070 |
Why?
|
Random Allocation | 2 | 2011 | 2394 | 0.070 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 777 | 0.070 |
Why?
|
California | 1 | 2012 | 1436 | 0.070 |
Why?
|
Patient-Centered Care | 3 | 2023 | 1448 | 0.070 |
Why?
|
Tobacco Use Disorder | 1 | 2013 | 708 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2910 | 0.070 |
Why?
|
Risk | 3 | 2018 | 9600 | 0.070 |
Why?
|
Laparoscopy | 2 | 2018 | 2037 | 0.070 |
Why?
|
Advisory Committees | 1 | 2011 | 796 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 1353 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1927 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2184 | 0.070 |
Why?
|
Maternal Exposure | 1 | 2013 | 1096 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6304 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2010 | 12421 | 0.060 |
Why?
|
Sulfonamides | 1 | 2015 | 1981 | 0.060 |
Why?
|
Chronic Disease | 2 | 2018 | 9355 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1296 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1883 | 0.060 |
Why?
|
Prospective Studies | 6 | 2023 | 54798 | 0.060 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2354 | 0.060 |
Why?
|
Women's Health | 1 | 2014 | 2082 | 0.060 |
Why?
|
Liver Diseases | 1 | 2013 | 1303 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2914 | 0.060 |
Why?
|
Postoperative Complications | 4 | 2020 | 15794 | 0.060 |
Why?
|
Treatment Failure | 1 | 2010 | 2655 | 0.060 |
Why?
|
Genetic Testing | 1 | 2017 | 3590 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2108 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2013 | 1390 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2235 | 0.050 |
Why?
|
Estrogens | 1 | 2010 | 1527 | 0.050 |
Why?
|
Fetal Development | 1 | 2009 | 777 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3734 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2014 | 1946 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13446 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2012 | 1584 | 0.050 |
Why?
|
Administration, Oral | 2 | 2021 | 4018 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3247 | 0.050 |
Why?
|
Laxatives | 1 | 2023 | 94 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7840 | 0.050 |
Why?
|
Biomedical Research | 2 | 2020 | 3457 | 0.050 |
Why?
|
Models, Structural | 1 | 2022 | 338 | 0.050 |
Why?
|
Maternal Age | 2 | 2016 | 804 | 0.050 |
Why?
|
Citalopram | 1 | 2024 | 402 | 0.050 |
Why?
|
Genomics | 1 | 2017 | 5926 | 0.050 |
Why?
|
Carbamazepine | 1 | 2022 | 224 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2041 | 0.050 |
Why?
|
Oxymorphone | 1 | 2020 | 6 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14644 | 0.040 |
Why?
|
Insurance, Health | 1 | 2012 | 2521 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5696 | 0.040 |
Why?
|
Filgrastim | 1 | 2019 | 130 | 0.040 |
Why?
|
Levonorgestrel | 1 | 2020 | 76 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6508 | 0.040 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.040 |
Why?
|
Sulfides | 1 | 2020 | 166 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2019 | 38 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6839 | 0.040 |
Why?
|
Valproic Acid | 1 | 2022 | 444 | 0.040 |
Why?
|
Acetates | 1 | 2020 | 314 | 0.040 |
Why?
|
Pain | 1 | 2014 | 5076 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 437 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3987 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13635 | 0.040 |
Why?
|
Oxycodone | 1 | 2020 | 144 | 0.040 |
Why?
|
Decision Making | 3 | 2020 | 3955 | 0.040 |
Why?
|
Insemination, Artificial | 1 | 2019 | 99 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1613 | 0.040 |
Why?
|
Constipation | 1 | 2023 | 568 | 0.040 |
Why?
|
Capital Financing | 1 | 2017 | 58 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2023 | 787 | 0.030 |
Why?
|
Fertility | 1 | 2022 | 768 | 0.030 |
Why?
|
Epilepsy | 1 | 2012 | 3317 | 0.030 |
Why?
|
Health Status | 1 | 2009 | 4084 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2024 | 1198 | 0.030 |
Why?
|
Recurrence | 2 | 2022 | 8506 | 0.030 |
Why?
|
Drug and Narcotic Control | 1 | 2015 | 144 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2017 | 1154 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 26276 | 0.030 |
Why?
|
HIV Infections | 1 | 2020 | 17530 | 0.030 |
Why?
|
Blood Pressure | 1 | 2009 | 8532 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1585 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2024 | 2711 | 0.030 |
Why?
|
Risk-Taking | 1 | 2018 | 1021 | 0.030 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 239 | 0.020 |
Why?
|
Drug Combinations | 1 | 2017 | 2074 | 0.020 |
Why?
|
Postpartum Period | 1 | 2018 | 1196 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1301 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4849 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2013 | 587 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2013 | 737 | 0.020 |
Why?
|
Oxygen | 1 | 2021 | 4242 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1573 | 0.020 |
Why?
|
Epidemiology | 1 | 2011 | 278 | 0.020 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2013 | 391 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2017 | 2132 | 0.020 |
Why?
|
Data Mining | 1 | 2013 | 561 | 0.020 |
Why?
|
Medicaid | 1 | 2021 | 2832 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15881 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3435 | 0.020 |
Why?
|
Infertility, Female | 1 | 2013 | 763 | 0.020 |
Why?
|
Specialization | 1 | 2011 | 779 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2649 | 0.020 |
Why?
|
Sweden | 1 | 2009 | 1381 | 0.020 |
Why?
|
Parity | 1 | 2009 | 930 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 950 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 1811 | 0.020 |
Why?
|
Gynecology | 1 | 2011 | 534 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1510 | 0.020 |
Why?
|
Obstetrics | 1 | 2011 | 679 | 0.010 |
Why?
|
Obesity | 2 | 2020 | 13078 | 0.010 |
Why?
|
Patient Discharge | 1 | 2017 | 3461 | 0.010 |
Why?
|
Program Evaluation | 1 | 2012 | 2501 | 0.010 |
Why?
|
Biological Products | 1 | 2012 | 942 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8224 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8698 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12821 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3845 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7872 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7416 | 0.010 |
Why?
|
Animals | 1 | 2007 | 168730 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5446 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 11092 | 0.000 |
Why?
|